与COVID-19相关的静脉血栓栓塞结局结果的比较分析:从2020年到2021-2022年的演变
Francisco Galeano-Valle1,2, Pablo Demelo-Rodríguez1,2, Rubén Alonso-Beato3,4
1Internal Medicine Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Journal of thrombosis and thrombolysis
|July 30, 2024
概括
在接种疫苗之前,患有静脉血栓栓塞 (VTE) 的COVID-19患者面临更高的风险. 接种疫苗后的引入,90天死亡率和重大出血风险在COVID-19相关的VTE患者中显著下降.
科学领域:
- 医学研究 医学研究
- 传染性疾病 传染性疾病
- 心脏病学 心脏病学
背景情况:
- 患有COVID-19的患者患有静脉血栓栓塞 (VTE) 的风险较高.
- 从2020年到2022年,COVID-19的景观随着疫苗和治疗方法的发展而变化.
- 这些干预措施对COVID-19相关的VTE结果的影响仍未得到充分研究.
研究的目的:
- 评估COVID-19患者在疫苗引入之前和之后的90天VTE相关结果.
- 为了比较所有原因的死亡率,重大出血率和静脉瘤复发率.
- 分析疫苗接种和新型治疗对临床结果的影响.
主要方法:
- 分析来自RIETE注册表的数据.
- 两个时期的比较:2020年3月至12月 (疫苗接种前) 和2021年3月至2022年12月 (疫苗接种后).
- 使用混合效应参数生存时间模型进行统计分析.
主要成果:
- 分析了1620名COVID-19相关的VTE患者;大多数 (74.1%) 来自2020年期间.
- 与疫苗接种后的时期相比,疫苗接种前期的90天死亡率 (aHR: 2.27) 和严重出血 (aHR: 2.91) 的风险增加了2倍以上.
- 复发性VTE的发病率很低,并且在不同时期之间很相似 (1.1%对0.7%).
结论:
- 引入COVID-19疫苗和新的治疗方法与COVID-19相关的VTE患者的改善结果有关.
- 在疫苗接种后的时期,90天死亡率和严重出血的显著下降被观察到.
- 这些发现突显了医学进步对COVID-19患者VTE管理的积极影响.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
659
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
659
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Venous Return
3.7K
The circulatory system plays a crucial role in ensuring the optimal functioning of the human body. One of its critical components is venous return - the process that completes the blood circulation cycle. This article will delve into the concept of venous return, how it works, and its significance to our health.
What is Venous Return?
Venous return refers to the rate at which blood flows back to the heart from the body's peripheral veins. It's an integral part of the circulatory system...
What is Venous Return?
Venous return refers to the rate at which blood flows back to the heart from the body's peripheral veins. It's an integral part of the circulatory system...
3.7K
Comparing the Survival Analysis of Two or More Groups
168
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
168
Overview of Systemic Veins
448
Systemic veins are crucial blood vessels that return deoxygenated blood from various body tissues back to the heart. There are three systemic veins that return deoxygenated blood to the heart, they are as follows.
The coronary sinus, the heart's principal vein, resides in the coronary sulcus on the heart's posterior aspect. This broad venous channel receives nearly all venous blood from the myocardium, the heart muscle. It is fed by three primary veins: the great cardiac vein, the...
The coronary sinus, the heart's principal vein, resides in the coronary sulcus on the heart's posterior aspect. This broad venous channel receives nearly all venous blood from the myocardium, the heart muscle. It is fed by three primary veins: the great cardiac vein, the...
448


